Records containing: Primary Mediastinal Large B-cell Lymphoma (PMBCL)

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2026-04-14
A Phase 1 Study of SynKIR-310, Autologous T Cells Transduced With CD19 KIR-CAR, in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
CLINICAL_TRIALS study record update · 2026-04-08
A Phase 1/2, Open-label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
CLINICAL_TRIALS study record update · 2026-04-03
CLIC-02: A Phase I Trial of CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
CLINICAL_TRIALS study record update · 2026-03-30
A Phase 1/2 Safety, Dose-finding, and Pharmacokinetics Study of VNX-101 Gene Therapy in Patients With Relapsed or Refractory CD19-Positive Hematologic Malignancies (SENTRY-CD19)
CLINICAL_TRIALS study record update · 2026-03-16
A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2026-03-16
A Multi-center, Single Arm, Open-label Phase 1/2 Clinical Trial to Evaluate Safety, and to Explore Efficacy of TC011(CD19 Targeted CAR-T) in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
CLINICAL_TRIALS study record update · 2026-03-05
A Phase II Trial of Pembrolizumab in Combination With Chimeric Antigen Receptor Therapy in Patients With Relapsed/Refractory Primary Mediastinal B-cell Lymphoma
CLINICAL_TRIALS study record update · 2026-03-03
A Phase 2 Trial to Evaluate the Efficacy and Safety of WZTL-002 in Patients With Relapsed or Refractory Large B-cell Lymphoma (ENABLE-2)
CLINICAL_TRIALS study record update · 2026-02-27
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects With Selected Relapsed/Refractory B Cell Malignancies
CLINICAL_TRIALS study record update · 2026-02-23
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies
CLINICAL_TRIALS study record update · 2026-01-12
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors: A Randomized Non-pharmacological Clinical Trial By The Fondazione Italiana Linfomi (FIL)
CLINICAL_TRIALS study record update · 2025-12-24
Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study by the Fondazione Italiana Linfomi.
CLINICAL_TRIALS study record update · 2025-10-03
Bio-CAR-T Study on Pre and Post-infusion CAR-T Cell Therapy
CLINICAL_TRIALS study record update · 2025-09-11
A Phase Ia Study of Tri-specific CAR19.20.22 Chimeric Antigen Receptor (CAR) T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
CLINICAL_TRIALS study record update · 2025-06-26
Retrospective Multicenter International Study on Prognostic Factors, Management And Outcome Of Primary Mediastinal Large B-Cell Lymphoma (PMLBCL) Patients With Central Nervous System (CNS) Involvement
CLINICAL_TRIALS study record update · 2025-02-10
A Phase 2 Study of Pembrolizumab (MK-3475) Every 6 Weeks (Q6W) in Participants With Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
CLINICAL_TRIALS study record update · 2024-04-01
A Multicenter Prospective Observational Study on Chimeric Antigen Receptor (CAR) T-cell Therapy for Lymphoma: Monitoring Feasibility, Efficacy, Toxicity and Biomarkers in a Real Life Setting
CLINICAL_TRIALS study record update · 2023-05-25
Expanded Access Program (EAP) to Provide Epcoritamab (GEN3013) to Eligible Patients With Relapsed or Refractory Large B-cell Lymphoma
CLINICAL_TRIALS study record update · 2023-05-12
Chimeric Antigen Receptor (CAR) Cell Therapy Related Cardiovascular Outcomes